Rare disease clinical research
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- GUYS AND ST THOMAS' NHS FOUNDATIONTRUST
Major London NHS hospital trust contributing clinical trial sites, patient cohorts, and translational expertise to rare disease and neurodevelopmental research.
“MCDS-Therapy (skeletal dysplasia drug repurposing), ARISE (sickle cell disease), and AIMS-2-TRIALS (autism/intellectual disability) all involve rare or underserved conditions.”
PrimaryUK6 projects - FAKULTNI NEMOCNICE MOTOL A HOMOLKA
Major Czech teaching hospital contributing clinical trial expertise in rare diseases: spinal cord injury, paediatric liver cancer, and Duchenne muscular dystrophy.
“All three H2020 projects address rare or severe conditions (paediatric liver cancer, spinal cord injury, DMD), pointing to a consistent rare disease clinical profile.”
PrimaryCZ3 projects - GEMEINNUTZIGE SALZBURGER LANDESKLINIKEN BETRIEBSGESELLSCHAFT
Austrian public university hospital contributing clinical research capacity in oncology and rare diseases across major European consortia.
“EJP RD (2019–2024) involved SALK as a third party in the European Joint Programme on Rare Diseases, connecting them to a broad rare disease research and patient network.”
AT2 projects